.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,283,255

« Back to Dashboard

Claims for Patent: 5,283,255

Title: Wavelength-specific cytotoxic agents
Abstract:A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
Inventor(s): Levy; Julia G. (Vancouver, CA), Dolphin; David (Vancouver, CA), Chow; Jack J. (Vancouver, CA), Sternberg; Ethan (Vancouver, CA)
Assignee: The University of British Columbia (Vancouver, CA)
Application Number:07/943,895
Patent Claims: 1. A method to detect, photosensitize, destroy or impair the functioning of target biological material which comprises contacting said target with an effective amount of a hydro-monobenzoporphyrin (Gp) having a light absorption maximum between 670-780 nm;

wherein the Gp is selected from the group consisting of ##STR17## and mixtures thereof and the metalated and labeled forms thereof, wherein each R.sup.1 and R.sup.2 independently selected from the group consisting of carbalkoxy (2-6C), alkyl (1-6C) sulfonyl, Aryl (6-10C) sulfonyl, aryl (6-10C); cyano; and --CONR.sup.5 CO-- wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C)

each R.sup.3 is independently carboxyalkyl (2-6C) or a salt, amide, ester or acylhydrazone thereof, or is alkyl (1-6C); and

R.sup.4 is CHCH.sub.2, CH.sub.2 OR.sup.4', --CHO, --COOR.sup.4 CH(OR.sup.4')CH.sub.3, CH(OR.sup.4')CH.sub.2 OR.sup.4', --CH(SR.sup.4')CH.sub.3, --CH(NR.sup.2)CH.sub.3, --CH(CN)CH.sub.3, --CH(COOR.sup.4')CH.sub.3, --CH((OOCR.sup.4')CH.sub.3, --CH(halo)CH or --CH(halo)CH.sub.2 (halo), wherein R.sup.4' is H, alkyl (1-6C) optionally substituted with a hydrophilic substituent, or

wherein R.sup.4 is an organic noninterfering group of <12C resulting from direct or indirect derivatization of vinyl, or

wherein R.sup.4 consists of 1-3 tetrapyrrole-type nuclei of the formula --L--P wherein --L-- is selected from the group consisting of ##STR18## and P is selected from the group consisting of Gp which is of the formula 1-6 but lacking R.sup.4 and conjugated through the position shown as occupied by R.sup.4 to L, and a porphyrin of the formula: ##STR19## wherein each R is independently H or lower alkyl (1-4C); wherein two of the bonds shown as unoccupied on adjacent rings are joined to R.sup.3 and one of the remaining bonds shown as unoccupied is joined to R.sup.4 and the other to L;

with the proviso that if R.sup.4 is CHCH.sub.2, both R.sup.3 cannot be carbalkoxyethyl;

and irradiating said target with light absorbed by said Gp.

2. The method of claim I wherein each R.sup.3 is --CH.sub.2 CH.sub.2 COOH or a salt, amide, ester or acylhydrazone thereof.

3. The method of claim 1 wherein each of R.sup.1 and R.sup.2 is carbalkoxy (2-6C).

4. The method of claim 2 wherein each of R.sup.1 and R.sup.2 is carbalkoxy (2-6C).

5. The method of claim 1 wherein the Gp has formula 3 or 4.

6. The method of claim 4 wherein the Gp has formula 3 or 4.

7. The method of claim 1 wherein

the Gp has formula 3 or 4 and mixtures thereof, and

wherein each R.sup.1 and R.sup.2 independently selected from the group consisting of carbalkoxy (2-6C), alkyl (1-6C) sulfonyl, aryl (6-10C) sulfonyl, aryl (6-10C) cyano; and --CONR.sup.5 CO-- wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyalkyl (2-6C) or a salt, amide, ester or acylhydrazone thereof, or is alkyl (1-6C);

R.sup.4 is CHCH.sub.2 CH.sub.2 OR.sup.4', --CHO, --COOR.sup.4', CH(OR.sup.4')CH.sub.3, CH(OR.sup.4')CH.sub.2 OR.sup.4', --CH(SR.sup.4')CH.sub.3, --CH(NR.sup.4'.sub.2)CH.sub.3, --CH(CN)CH.sub.3, --CH(COOR.sup.4')CH.sub.3, --CH((OOCR.sup.4')CH.sub.3, --CH(halo)CH.sub.3, or --CH(halo)CH.sub.2 (halo), wherein R.sup.4' is H, alkyl (1-6C) optionally substituted with a hydrophilic substituent.

8. The method of claim 1 wherein

the Gp has formula 3 or 4 and mixtures thereof, and

wherein each R.sup.1 and R.sup.2 is independently selected from the group consisting of carbalkoxy, alkyl (1-6C) sulfonyl, aryl (6-10C) sulfonyl, aryl (6-10C) cyano; and --CONR.sup.5 CO-- wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyalkyl (2-6C) or a salt, amide, ester or acylhydrazone thereof, or is alkyl (1-6C); and

wherein R.sup.4 is a substituent containing 1-3 tetrapyrrole-type nuclei, of the formula --L--P as herein defined.

9. The method of claim 1 wherein the target materials are cells or tissue harbored in a subject and said contacting comprises administering the Gp in vivo to said subject harboring said cells or tissue.

10. The method of claim 9 wherein the administering is by an oral route.

11. The method of claim 9 wherein the administering is topical.

12. The method of claim 9 wherein the administering is by injection.

13. The method of claim 9 wherein the Gp further contains a label.

14. The method of claim 13 wherein the label is selected from the group consisting of technetium, gallium and indium.

15. The method of claim 1 wherein the target is contained in a biological fluid.

16. The method of claim 15 wherein the biological fluid is blood or blood plasma.

17. The method of claim 16 wherein the fluid is treated ex vivo.

18. The method of claim 1 wherein said method is to photosensitize, destroy or impair the functioning of target biological material, and where said irradiating is conducted with light of wavelength between 670-780 nm.

19. The method of claim 18 wherein said irradiation is supplied by a laser.

20. The method of claim 18 wherein said irradiation is supplied by a light-emitting diode.

21. The method of claim 1 wherein the target material is the lesions of psoriasis.

22. The method of claim 1 wherein the target material is atherosclerotic plaque.

23. The method of claim 1 wherein the target material is a virus.

24. The method of claim 1 which is to detect the target biological material and wherein said irradiating excites said Gp to emit fluorescence.

25. A method to detect or impair the metabolism of or to effect the destruction of target virus, cells, or tissues which comprises contacting said target with an effective amount of the Gp compound as defined in claim 1, or a pharmaceutical composition thereof, and irradiating the contacted virus, cells, or tissues with light absorbed by the Gp.

26. The method of claim 25 wherein the target comprises cells selected from tumor cells, T-suppressor cells and infective cells.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc